In 2024, BioAgilytix continued to enhance its capabilities, expand its lab footprint and bring on industry leaders to support its next phase of growth in providing comprehensive bioanalytical services from preclinical through phase III clinical trials. CEO Davide Molho signed on new Chief Growth Officer Ed Amat to further strengthen commercial efforts as well as a new Chief Information Officer, Chief People Officer and Head of Marketing. BioAgilytix expanded its Australian presence with a new 3,000 sq. ft. site in Melbourne and began a significant expansion of its CMC services in Durham, NC. Despite a challenging macro environment, BioAgilytix remains well positioned as a premium player with a leading reputation and continues to make significant investments to better serve its customer base in 2025 and beyond.